Known targets — ChEMBL curated mechanism
GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BM
The experimentally established mechanism targets of Amantadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D known ✓ | O15399 | 2/20 | 0.48 |
| ▸ | GRIN3B known ✓ | O60391 | 2/20 | 0.48 |
| ▸ | GRIN1 known ✓ | Q05586 | 2/20 | 0.48 |
| ▸ | GRIN2A known ✓ | Q12879 | 2/20 | 0.48 |
| ▸ | GRIN2B known ✓ | Q13224 | 2/20 | 0.48 |
| ▸ | GRIN2C known ✓ | Q14957 | 2/20 | 0.48 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.48 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.48 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | STAT6 | P42226 | 1/20 | 0.48 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amantadine SCHEMBL27831277 | 0.72 | GRIN2D (0.56) | LMNAGRIN2DGRIN3BGRIN1GRIN2A | |
| Phthalic Anhydride SCHEMBL28135943 | 0.72 | TDP1 (0.88) | TDP1ALOX15LMNANFKB1TSHR | |
| Phthalic Anhydride SCHEMBL220 | 0.72 | TDP1 (1.00) | TDP1ALOX15LMNANFKB1TSHR | |
| Phthalic Anhydride SCHEMBL29356227 | 0.72 | TDP1 (1.00) | TDP1ALOX15LMNANFKB1TSHR | |
| Phthalic Anhydride SCHEMBL380499 | 0.72 | TDP1 (1.00) | TDP1ALOX15LMNANFKB1TSHR | |
| SCHEMBL13173722 | 0.70 | DDB1 (0.41) | TDP1LMNAGRIN2DGRIN3BGRIN1 | |
| SCHEMBL15436465 | 0.70 | DDB1 (0.41) | TDP1LMNAGRIN2DGRIN3BGRIN1 | |
| Phthalic Anhydride SCHEMBL28376733 | 0.70 | TDP1 (0.82) | TDP1ALOX15LMNANFKB1TSHR | |
| Phthalic Anhydride SCHEMBL19642997 | 0.70 | TDP1 (0.82) | TDP1ALOX15LMNATSHRTHRB | |
| Phthalic Anhydride SCHEMBL29189778 | 0.70 | TDP1 (0.82) | TDP1ALOX15LMNATSHRTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8241371-B2 | Concurrent precipitation of active material and crystal former from solution or suspension in presence of supercritical fluid such as carbon dioxide | THAR PHARMACEUTICALS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| EP-2117666-A1 | METHOD OF CREATING CRYSTALLINE SUBSTANCES | Thar Pharmaceuticals Inc. (US) | 2009-11-18 | — | — | EP | disclosed |
| US-20080280858-A1 | METHOD OF CREATING CRYSTALLINE SUBSTANCES | THAR PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| WO-2008096144-A1 | METHOD OF CREATING CRYSTALLINE SUBSTANCES | THAR PHARMACEUTICALS INC. (US) | 2008-08-14 | — | — | WO | disclosed |